Novo rises on Wegovy sales leap, but warns of a slowdown
While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating "intensifying competition and continued pricing pressure within diabetes and obesity care" in 2025.
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Its a healthy morning as Novo Nordisk says sales of its obesity drug, Wegovy, rose 57% last year while Brits are buying more ...
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
General Pharmaceutical Council issues new guidance following reports people are lying about their weight in online forms and submitting photos of themselves in baggy clothes ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback